Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05002764
NCT05002764UnknownNot Applicable

Differential Vulnerability of Individual Thalamic Nuclei: Toward New Biomarkers in Multiple Sclerosis

University Hospital, Bordeaux1 site in 1 country2,000 target enrollmentStarted: July 1, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
2,000
Locations
1
Primary Endpoint
Volume of thalamic nuclei
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The thalamus is composed of several nuclei interlocked in a complex anatomy. In multiple sclerosis (MS), the thalamus can be altered due to disconnection by white matter lesions and due to direct damages that could be partly mediated by CSF. Due to such pathophysiology and complex anatomy, some nuclei could be more vulnerable to multiple sclerosis than others. We will test this hypothesis by using a new algorithm to automatically segment several nuclei that we will be applied to the French national MS database

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Volume of thalamic nuclei

Time Frame: At inclusion in the cohort

Volume of individual thalamic nuclei according to disease duration.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
University Hospital, Bordeaux
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous SystemMultiple SclerosisCentral Nervous System Disease
NCT00794352National Institute of Allergy and Infectious Diseases (NIAID)2,400
Active, not recruiting
Not Applicable
Characterisation of multiple sclerosis pathology by ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques[Charakterisierung der Multiple Sklerose Pathologie durch ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIPPatients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first sign of MS early in the course, N=15) are planned to be investigated in the proposed clinical trial.MedDRA version: 8.1Level: LLTClassification code 10028245Term: Multiple sclerosis
EUCTR2006-001337-17-DEMax-Planck-Institute of Psychiatry
Unknown
Not Applicable
Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
NCT04073940University of Illinois at Urbana-Champaign30
Recruiting
Not Applicable
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple SclerosisMultiple Sclerosis (MS)
NCT05633875Assistance Publique - Hôpitaux de Paris80
Unknown
Not Applicable
Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance ImagingSpinal Cord AtrophyAtrophy BrainCognitive ChangeMultiple Sclerosis
NCT03706118Dana Horakova102